サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1300996

皮膚科CROの市場規模、シェア、動向分析レポート：タイプ別、サービスタイプ別、地域別、セグメント予測、2023年～2030年

Dermatology CRO Market Size, Share & Trends Analysis Report By Type (Preclinical, Clinical), By Service Type (Laboratory, Regulatory/Medical Affairs), By Region (North America, Asia Pacific), And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
皮膚科CROの市場規模、シェア、動向分析レポート：タイプ別、サービスタイプ別、地域別、セグメント予測、2023年～2030年
出版日: 2023年06月06日
発行: Grand View Research
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

皮膚科CRO市場の成長と動向

GrandView Research, Inc.の最新レポートによると、世界の皮膚科CRO市場規模は2030年までに80億5,790万米ドルに達し、予測期間中のCAGRは6.8％を記録すると予測されています。

皮膚科疾患に関連する疾病負担を軽減するためにCRO（医薬品開発業務受託機関）の流入が増加していることが、この市場の主要な促進要因です。さらに、ニキビを治療するための抗感染剤、抗炎症剤、局所麻酔剤、エモリエント剤、洗浄剤などの皮膚科外用薬に対する需要の高まりは、市場成長を促進する主な要因です。迅速な診断に対する需要の高さ、皮膚がんやその他の皮膚疾患の有病率の増加、皮膚疾患に関する意識の高まりは、市場成長を後押しする主な要因です。

世界中で皮膚疾患の症例が増加していることが、予測期間中の市場成長を促進すると予想されます。アトピー性皮膚炎は最も一般的な炎症性皮膚疾患の一つであり、米国では患者の約5～10%が罹患しています。さらに、皮膚がんは米国で最も多いがんです。米国皮膚科学会によると、約5人に1人が一生のうちに皮膚がんを発症します。また、米国では毎日約9500人が皮膚がんと診断されていると推定されています。COVID-19の流行は市場に大きな影響を与えました。

皮膚科を含む多くの治療分野における臨床試験がCOVID-19パンデミックの影響を受けた。いくつかの臨床試験は一時的に延期または中止され、研究のスケジュールや進捗に影響を与えました。皮膚科CROのサービスは臨床試験活動と密接に結びついているため、この混乱は皮膚科CROの成長と収益に影響を与えると予想されます。さらに、皮膚科業界における特許切れや研究開発プログラムへの投資の増加は、今後数年間の市場成長を促進すると予想される主な要因です。例えば、2022年2月、Recipharm社は米国におけるmRNA生物製剤の提供を拡大するため、CDMO Arranta Bio社を買収しました。この買収により、同社はがん、乾癬、感染症、その他の疾患領域における医薬品開発能力を向上させることが期待されます。

皮膚科CRO市場レポートハイライト

  • タイプ別では、臨床分野が2022年に76.10%と最大の売上シェアを占めました。この背景には、臨床試験の世界化、技術の進歩、臨床試験を実施する皮膚科CROに対する需要の増加があります。
  • サービスタイプ別では、薬事/医療分野が予測期間中に大きな市場シェアを示すと予想されます。新製品の承認取得需要の増加や世界の医薬品規制の相違が、同分野の成長を促す主な要因となっています。
  • アジア太平洋地域は、2022年に43.29%を超える最大の収益シェアを獲得しました。これは、人口の多様性、皮膚疾患の有病率の高さ、規制の枠組みの改善、患者の募集と確保が容易であること別。
  • コビド後の臨床試験の急増は、CROが皮膚科領域に参入する有利な機会を提供しました。例えば、2022年 1月、バイアルはその子会社であるVial Dermatology CROを通じて皮膚科領域のアウトソーシングサービスを開始しました。そこでは、米国内の35の皮膚科クリニックと提携し、より迅速な臨床試験を提供しています。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
  • 地域の範囲
  • 推定・予測のタイムライン
  • 目的
  • 調査手法
  • 情報調達
  • 情報またはデータ分析
  • 市場の形成と検証
  • モデル詳細
  • 二次情報のリスト
  • 略語のリスト

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメントの見通し
  • 競合考察

第3章 皮膚科CRO市場変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 皮膚科CRO市場分析ツール
    • 業界分析- ポーターの分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 皮膚科CRO市場：タイプの推定・動向分析

  • 皮膚科CRO市場、タイプ別：セグメントダッシュボード
  • 皮膚科CRO市場、タイプ別：変動分析
    • 創薬
    • 前臨床
    • 臨床

第5章 皮膚科CRO市場：サービスタイプの推定・動向分析

  • 皮膚科CRO市場、サービスタイプ別：セグメントダッシュボード
  • 皮膚科CRO市場、サービスタイプ別：変動分析
    • プロジェクト管理/臨床供給管理
    • データ管理
    • 規制・医療関係
    • メディカルライティング
    • 臨床モニタリング
    • 品質管理・保証
    • 生物統計
    • 調査員への支払い
    • 患者および施設の募集
    • ラボ
    • テクノロジー
    • その他

第6章 皮膚科CRO市場：地域の推定・動向分析

  • 地域市場シェア分析、2022年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 北米
    • 市場推計・予測、2018年から2030年（収益）
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • インド
    • 中国
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • チリ
  • MEA
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • イラン
    • クウェート

第7章 競合情勢

  • 市場参入企業の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレイヤー
    • 企業の市場シェア分析、2022年
  • 企業プロファイル
    • IQVIA, Inc.
    • Labcorp Drug Development
    • Aragen Life Sciences Ltd
    • Pharmaceutical Product Development, Inc.（Thermo Fisher Scientific Inc.）
    • Parexel International Corporation
    • Charles River Laboratories
    • Icon, Plc
    • Medidata
    • Syneos Health
    • S Pharmaron
    • Wuxi Apptec
    • Medpace
    • CTI Clinical Trial &Consulting
    • Bioskin
    • Proinnovera GmbH
    • Biorasi, LLC
    • Javara
    • TFS
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Dermatology CRO Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 North America Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 North America Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 8 Canada Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 Canada Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 10 Europe Dermatology CRO Market, By Region, 2018 - 2030 (USD Million)
  • Table 11 Europe Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 12 Europe Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 13 UK Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 14 UK Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 15 Germany Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Germany Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 17 France Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 France Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 19 Italy Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Italy Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 21 Spain Dermatology CRO Market, By Test Type, 2018 - 2030 (USD Million)
  • Table 22 Spain Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 23 Denmark Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 Denmark Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 25 Sweden Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Sweden Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 27 Norway Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Norway Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Dermatology CRO Market, By Region, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 32 China Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 33 China Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 34 Japan Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Japan Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 36 India Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 37 India Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 38 Australia Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 39 Australia Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 40 South Korea Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 South Korea Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 42 Thailand Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 43 Thailand Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Dermatology CRO Market, By Region, 2018 - 2030 (USD Million)
  • Table 45 Latin America Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 46 Latin America Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 47 Brazil Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Brazil Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 49 Mexico Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Mexico Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 51 Argentina Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 52 Argentina Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 53 Colombia Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Colombia Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 55 Chile Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 Chile Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 57 Middle East And Africa Dermatology CRO Market, By Region, 2018 - 2030 (USD Million)
  • Table 58 Middle East And Africa Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Middle East And Africa Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 60 South Africa Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 South Africa Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 64 UAE Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 UAE Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 66 Iran Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 Iran Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)
  • Table 68 Israel Dermatology CRO Market, By Type, 2018 - 2030 (USD Million)
  • Table 69 Israel Dermatology CRO Market, By Service Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Dermatology CRO market outlook, 2018 - 2030
  • Fig. 9 Market trends & outlook
  • Fig. 10 Penetration & growth prospect mapping by service, 2022
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 SWOT Analysis, By factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 16 Global dermatology CRO market: Type movement analysis
  • Fig. 17 Drug discovery market 2018 - 2030 (USD Million)
  • Fig. 18 Target validation market 2018 - 2030 (USD Million)
  • Fig. 19 Lead identification market 2018 - 2030 (USD Million)
  • Fig. 20 Lead optimization market 2018 - 2030 (USD Million)
  • Fig. 21 Preclinical market 2018 - 2030 (USD Million)
  • Fig. 22 Clinical market 2018 - 2030 (USD Million)
  • Fig. 23 Phase I market 2018 - 2030 (USD Million)
  • Fig. 24 Phase II market 2018 - 2030 (USD Million)
  • Fig. 25 Phase III market 2018 - 2030 (USD Million)
  • Fig. 26 Phase IV market 2018 - 2030 (USD Million)
  • Fig. 27 Global dermatology CRO market: Service Type movement analysis
  • Fig. 28 Project management/clinical supply management market 2018 - 2030 (USD Million)
  • Fig. 29 Data management market 2018 - 2030 (USD Million)
  • Fig. 30 Regulatory/medical affairs market 2018 - 2030 (USD Million)
  • Fig. 31 Medical writing market 2018 - 2030 (USD Million)
  • Fig. 32 Clinical monitoring market 2018 - 2030 (USD Million)
  • Fig. 33 Quality management/ assurance market 2018 - 2030 (USD Million)
  • Fig. 34 Bio-statistics market 2018 - 2030 (USD Million)
  • Fig. 35 Investigator payments market 2018 - 2030 (USD Million)
  • Fig. 36 Laboratory market 2018 - 2030 (USD Million)
  • Fig. 37 Patient and site recruitment market 2018 - 2030 (USD Million)
  • Fig. 38 Technology market 2018 - 2030 (USD Million)
  • Fig. 39 Others market 2018 - 2030 (USD Million)
  • Fig. 40 Regional market place: Key takeaway
  • Fig. 41 Dermatology CRO regional outlook, 2022 & 2030
  • Fig. 42 North America dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 47 France dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 48 UK dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 49 Spain dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 55 China dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 57 India dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 62 Mexico dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 64 Colombia dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 65 Chile dermatology CRO market, 2018 - 2030 (USD Million)
  • Fig. 66 Middle East & Africa Dermatology CRO Market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa Dermatology CRO Market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia Dermatology CRO Market, 2018 - 2030 (USD Million)
  • Fig. 69 UAE Dermatology CRO Market, 2018 - 2030 (USD Million)
  • Fig. 70 Israel Arabia Dermatology CRO Market, 2018 - 2030 (USD Million)
  • Fig. 71 Iran Dermatology CRO Market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait Dermatology CRO Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-635-9

Dermatology CRO Market Growth & Trends

The global dermatology CRO market size is expected to reach USD 8,057.9 million by 2030, registering a CAGR of 6.8% over the forecast period, according to a new report by Grand View Research, Inc. Rising influx of contract research organizations (CROs) to mitigate the disease burden associated with dermatological conditions is a key driver for this market. Moreover, the rising demand for topical dermatological medications, such as anti-infective, anti-inflammatory agents, local anesthetics, emollients, and cleansers, to cure acne are major factors driving the market growth. High demand for speedy diagnosis, an increase in the prevalence of skin cancer and other skin problems, and increased awareness regarding skin diseases are major factors boosting the market growth.

An increase in cases of skin disease across the globe is expected to propel the market growth in the forecast period. Atopic dermatitis is one of the most common inflammatory skin diseases, affecting around 5-10% of individuals in the U.S. Around one in three individuals in the country with atopic dermatitis have moderate-to-severe disease. Moreover, skin cancer is the most common cancer in the U.S. According to the American Academy of Dermatology, around 1 in 5 individuals would develop skin cancer in their lifetime. In addition, it is estimated that around 9500 individuals in the country are diagnosed with skin cancer every day. The COVID-19 pandemic significantly impacted the market.

Clinical trials in numerous therapeutic fields, including dermatology, were impacted by the COVID-19 pandemic. Several clinical trials were temporarily delayed or halted, impacting the timelines and progress of research studies. This disruption is expected to affect the growth and revenue of dermatology CROs, as their services are closely tied to clinical trial activities. Furthermore, patent expiration in the dermatology industry and growing investment in R&D programs are key factors anticipated to drive market growth in the coming years. For instance, in February 2022, Recipharm acquired CDMO Arranta Bio to expand its mRNA biologics offerings in the U.S. This acquisition is expected to improve the company's capabilities in developing medications in the area of cancer, psoriasis, infectious diseases, and other diseases.

Dermatology CRO Market Report Highlights

  • Based on type, the clinical segment accounted for the largest revenue share of 76.10% in 2022. This is attributed to the globalization of clinical trials, technological advancements, and an increase in demand for dermatology CROs to conduct clinical trials
  • Based on service type, the regulatory/medical affairs segment is expected to show a significant market share in the forecast period. Increasing demand to obtain approval for new products and differences in drug regulations globally are some of the major factors driving the segment growth
  • Asia Pacific captured the largest revenue share of over 43.29% in 2022. This is due to the diversity in population, high prevalence of skin disorders, improving regulatory framework, and, the ease with which patients may be recruited and retained
  • A post-covid surge in clinical trials provided a lucrative opportunity for CROs to enter the dermatology space. For instance, in January 2022, Vial started providing dermatology outsourcing services via its arm Vial Dermatology CRO. Wherein, they partnered with 35 dermatology clinics in the U.S. to provide faster clinical trials

Table of Content

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Type
    • 1.1.3. Service Type
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Dermatology CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing adoption of advanced technologies
      • 3.2.1.2. Growing interest to look more appealing
      • 3.2.1.3. Increasing outsourcing of R&D activities
      • 3.2.1.4. Favorable environment for clinical trials in developing countries
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality issues of CRO services
      • 3.2.2.2. Intellectual property rights issues
  • 3.3. Dermatology CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Dermatology CRO Market: Type Estimates & Trend Analysis

  • 4.1. Dermatology CRO Market, By Type: Segment Dashboard
  • 4.2. Dermatology CRO Market, By Type: Movement Analysis
  • 4.3. Dermatology CRO Market Estimates & Forecasts, By Type, 2018 - 2030
    • 4.3.1. Drug Discovery
      • 4.3.1.1. Drug Discovery Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Target Validation
      • 4.3.1.2.1. Target Validation Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Lead Identification
      • 4.3.1.3.1. Lead Identification Market, 2018 to 2030 (USD Million)
      • 4.3.1.4. Lead Optimization
      • 4.3.1.4.1. Lead Optimization Market, 2018 to 2030 (USD Million)
    • 4.3.2. Preclinical
      • 4.3.2.1. Preclinical Market, 2018 to 2030 (USD Million)
    • 4.3.3. Clinical
      • 4.3.3.1. Clinical Market, 2018 to 2030 (USD Million)
      • 4.3.3.2. Phase I
      • 4.3.3.2.1. Phase I Market, 2018 to 2030 (USD Million)
      • 4.3.3.3. Phase II
      • 4.3.3.3.1. Phase II Market, 2018 to 2030 (USD Million)
      • 4.3.3.4. Phase III
      • 4.3.3.4.1. Phase III Market, 2018 to 2030 (USD Million)
      • 4.3.3.5. Phase IV
      • 4.3.3.5.1. Phase IV Market, 2018 to 2030 (USD Million)

Chapter 5. Dermatology CRO Market: Service Type Estimates & Trend Analysis

  • 5.1. Dermatology CRO Market, By Service Type: Segment Dashboard
  • 5.2. Dermatology CRO Market, By Service Type: Movement Analysis
  • 5.3. Dermatology CRO Market Estimates & Forecasts, By Service Type, 2018 - 2030
    • 5.3.1. Project Management/Clinical Supply Management
      • 5.3.1.1. Project Management/Clinical Supply Management Market, 2018 to 2030 (USD Million)
    • 5.3.2. Data Management
      • 5.3.2.1. Data Management Market, 2018 to 2030 (USD Million)
    • 5.3.3. Regulatory/Medical Affairs
      • 5.3.3.1. Regulatory/Medical Affairs Market, 2018 to 2030 (USD Million)
    • 5.3.4. Medical Writing
      • 5.3.4.1. Medical Writing Market, 2018 to 2030 (USD Million)
    • 5.3.5. Clinical Monitoring
      • 5.3.5.1. Clinical Monitoring Market, 2018 to 2030 (USD Million)
    • 5.3.6. Quality Management/ Assurance
      • 5.3.6.1. Quality Management/ Assurance Market, 2018 to 2030 (USD Million)
    • 5.3.7. Bio-statistics
      • 5.3.7.1. Bio-statistics Market, 2018 to 2030 (USD Million)
    • 5.3.8. Investigator Payments
      • 5.3.8.1. Investigator Payments Market, 2018 to 2030 (USD Million)
    • 5.3.9. Laboratory
      • 5.3.9.1. Laboratory Market, 2018 to 2030 (USD Million)
    • 5.3.10. Patient and site Recruitment
      • 5.3.10.1. Patient and site Recruitment Market, 2018 to 2030 (USD Million)
    • 5.3.11. Laboratory
      • 5.3.11.1. Laboratory Market, 2018 to 2030 (USD Million)
    • 5.3.12. Technology
      • 5.3.12.1. Technology Market, 2018 to 2030 (USD Million)
    • 5.3.13. Others
      • 5.3.13.1. Others Market, 2018 to 2030 (USD Million)

Chapter 6. Dermatology CRO Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2022 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. North America
    • 6.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Competitive Scenario
      • 6.5.1.3. Regulatory Framework
      • 6.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 6.5.3. France
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 6.5.4. Italy
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Competitive Scenario
      • 6.6.1.3. Regulatory Framework
      • 6.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 6.6.2. India
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 6.6.6. Thailand
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Competitive Scenario
      • 6.7.1.3. Regulatory Framework
      • 6.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 6.7.2. Mexico
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
    • 6.7.4. Colombia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
    • 6.7.5. Chile
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Competitive Scenario
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Competitive Scenario
      • 6.8.1.3. Regulatory Framework
      • 6.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 6.8.3. UAE
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 6.8.4. Israel
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Israel Market Estimates and Forecasts, 2018 - 2030
    • 6.8.5. Iran
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Competitive Scenario
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Iran Market Estimates and Forecasts, 2018 - 2030
    • 6.8.6. Kuwait
      • 6.8.6.1. Key Country Dynamics
      • 6.8.6.2. Competitive Scenario
      • 6.8.6.3. Regulatory Framework
      • 6.8.6.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
    • 7.1.1. Innovators
    • 7.1.2. Market Leaders
    • 7.1.3. Emerging Players
    • 7.1.4. Company Market Share Analysis, 2022
  • 7.2. Company Profiles
    • 7.2.1. IQVIA, Inc.
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Financial Performance
      • 7.2.1.3. Service Benchmarking
      • 7.2.1.4. Strategic Initiatives
    • 7.2.2. Labcorp Drug Development
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Financial Performance
      • 7.2.2.3. Service Benchmarking
      • 7.2.2.4. Strategic Initiatives
    • 7.2.3. Aragen Life Sciences Ltd
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Financial Performance
      • 7.2.3.3. Service Benchmarking
      • 7.2.3.4. Strategic Initiatives
    • 7.2.4. Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific Inc.)
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Financial Performance
      • 7.2.4.3. Service Benchmarking
      • 7.2.4.4. Strategic Initiatives
    • 7.2.5. Parexel International Corporation
      • 7.2.5.1. Company Overview
      • 7.2.5.2. Financial Performance
      • 7.2.5.3. Service Benchmarking
      • 7.2.5.4. Strategic Initiatives
    • 7.2.6. Charles River Laboratories
      • 7.2.6.1. Company Overview
      • 7.2.6.2. Financial Performance
      • 7.2.6.3. Service Benchmarking
      • 7.2.6.4. Strategic Initiatives
    • 7.2.7. Icon, Plc
      • 7.2.7.1. Company Overview
      • 7.2.7.2. Financial Performance
      • 7.2.7.3. Service Benchmarking
      • 7.2.7.4. Strategic Initiatives
    • 7.2.8. Medidata
      • 7.2.8.1. Company Overview
      • 7.2.8.2. Financial Performance
      • 7.2.8.3. Service Benchmarking
      • 7.2.8.4. Strategic Initiatives.
    • 7.2.9. Syneos Health
      • 7.2.9.1. Company Overview
      • 7.2.9.2. Financial Performance
      • 7.2.9.3. Service Benchmarking
      • 7.2.9.4. Strategic Initiatives
    • 7.2.10. S Pharmaron
      • 7.2.10.1. Company Overview
      • 7.2.10.2. Financial Performance
      • 7.2.10.3. Service Benchmarking
      • 7.2.10.4. Strategic Initiatives
    • 7.2.11. Wuxi Apptec
      • 7.2.11.1. Company Overview
      • 7.2.11.2. Financial Performance
      • 7.2.11.3. Service Benchmarking
      • 7.2.11.4. Strategic Initiatives
    • 7.2.12. Medpace
      • 7.2.12.1. Company Overview
      • 7.2.12.2. Financial Performance
      • 7.2.12.3. Service Benchmarking
      • 7.2.12.4. Strategic Initiatives
      • 7.2.12.5. CTI Clinical Trial & Consulting
    • 7.2.13. CTI Clinical Trial & Consulting
      • 7.2.13.1. Company Overview
      • 7.2.13.2. Financial Performance
      • 7.2.13.3. Service Benchmarking
      • 7.2.13.4. Strategic Initiatives
    • 7.2.14. Bioskin
      • 7.2.14.1. Company Overview
      • 7.2.14.2. Financial Performance
      • 7.2.14.3. Service Benchmarking
      • 7.2.14.4. Strategic Initiatives
    • 7.2.15. Proinnovera GmbH
      • 7.2.15.1. Company Overview
      • 7.2.15.2. Financial Performance
      • 7.2.15.3. Service Benchmarking
      • 7.2.15.4. Strategic Initiatives
    • 7.2.16. Biorasi, LLC
      • 7.2.16.1. Company Overview
      • 7.2.16.2. Financial Performance
      • 7.2.16.3. Service Benchmarking
      • 7.2.16.4. Strategic Initiatives
    • 7.2.17. Javara
      • 7.2.17.1. Company Overview
      • 7.2.17.2. Financial Performance
      • 7.2.17.3. Service Benchmarking
      • 7.2.17.4. Strategic Initiatives
    • 7.2.18. TFS
      • 7.2.18.1. Company Overview
      • 7.2.18.2. Financial Performance
      • 7.2.18.3. Service Benchmarking
      • 7.2.18.4. Strategic Initiatives